Abstract:The Human Immunodeficiency Virus (HIV) genome encodes three major structural proteins common to all retroviruses (Gag, Pol and Env), two regulatory proteins (Tat and Rev) that are essential for viral replication, and four accessory proteins (Nef, Vif, Vpu, Vpr). While accessory proteins were initially reported to be unnecessary for viral growth, their importance as virulence factors is now being more and more appreciated: they can dramatically alter the course and severity of viral infection, replication and disease progression. None of the HIV accessory proteins display enzymatic activity: they rather act altering cellular pathways via multiple protein-protein interactions with a number of host cell factors. All currently approved anti-HIV drugs target pol and env encoded proteins. Therefore, widening the molecular targets of HIV therapy by additionally targeting accessory proteins may expand treatment options, resulting in high impact effective new therapy. In this review we present the state of the art of compounds that target HIV accessory proteins. Most of the research has focused on the inhibition of specific accessory proteins/host cell partner interactions. Promising compounds have been found within different classes of molecules: small natural and synthetic molecules, peptides and proteins, oligonucleotides, in particular those used as RNA interference (RNAi) tools. With the assortment of compounds available, especially against Nef and Vif functions, the demonstration of the clinical efficacy of the new anti-HIV-1 drugs targeting accessory proteins is next challenge.

Recent Progress in the Development of HIV-1 Capsid Protein Inhibitors

Recent progress on functional cure for acquired immunodeficiency syndrome

Research Progress of HIV-1 Integrase and Its Inhibitors

An Insight on Medicinal Aspects of Novel HIV-1 Capsid Protein Inhibitors

Capsid (CA) protein as a novel drug target: recent progress in the research of HIV-1 CA inhibitors.

Clinical Development and Application of HIV Entry Inhibitors

Development Of Protein- And Peptide-Based Hiv Entry Inhibitors Targeting Gp120 Or Gp41

[Progress in the Study of HIV Capsid Structure and Drug Discovery].

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Advances in Non-Peptidomimetic HIV Protease Inhibitors.

Inhibitors from Natural Products to HIV-1 Reverse Transcriptase, Protease and Integrase

The advances of anti-HIV-1 drugs

Recent progress of inhibitors targeting HIV-1 NCp7

Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

Research Strategy for Short-Peptide Fusion Inhibitors Based on 6-HB Core Structure against HIV-1: A Review

New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle.

The successes and failures of HIV drug discovery

The Role of Capsid in the Early Steps of HIV-1 Infection: New Insights into the Core of the Matter

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies

Design, Synthesis, and Mechanistic Study of 2-Pyridone-bearing Phenylalanine Derivatives As Novel HIV Capsid Modulators

Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?